Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53

Mughal, 2015, An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms, Haematologica, 100, 1117, 10.3324/haematol.2014.114660 Mangaonkar, 2020, Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients, Leukemia, 34, 656, 10.1038/s41375-019-0574-x Bose, 2018, Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable, Blood, 132, 2100, 10.1182/blood-2018-05-848473 Jeromin, 2013, High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms, Haematologica, 98, e15, 10.3324/haematol.2012.072538 Harutyunyan, 2011, p53 lesions in leukemic transformation, N Engl J Med, 364, 488, 10.1056/NEJMc1012718 DiNardo, 2014, Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy, Leukemia, 28, 958, 10.1038/leu.2014.8 Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544 Kubesova, 2018, Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status, Leukemia, 32, 450, 10.1038/leu.2017.230 Wang, 2014, Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms, Blood, 123, 2645, 10.1182/blood-2014-02-553800 Greenfield, 2018, The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms, J. Transl. Med., 16, 360, 10.1186/s12967-018-1729-7 Assi, 2018, A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms, Am. J. Hematol., 93, 277, 10.1002/ajh.24972